<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968109</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-020</org_study_id>
    <secondary_id>2014-002605-38</secondary_id>
    <nct_id>NCT01968109</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors</brief_title>
  <official_title>A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability and effectiveness of
      experimental medication BMS-986016 administered alone and in combination with nivolumab in
      patients with solid tumors that have spread and/or cannot be removed by surgery.

      The following tumor types are included in this study:

      Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell
      carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that
      have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously
      been treated with immunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with Adverse Events (AEs)</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
    <description>Grade 3 or higher per CTCAE v4 (Common Terminology Criteria for Adverse Events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
    <description>Grade 3 or higher per CTCAE v4 ( Common Terminology Criteria for Adverse Events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Deaths</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with laboratory abnormalities in blood</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with laboratory abnormalities in blood serum</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with laboratory abnormalities in urine</measure>
    <time_frame>Approximately Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AEs in the Broad Scope MedDRA Anaphylactic Reaction SMQ</measure>
    <time_frame>Approximately 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with AEs leading to discontinuation of treatment</measure>
    <time_frame>Approximately up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of a dosing interval (Ctau) [Eg: concentration at 336 hours] of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of area under the concentration-time curve (AUC) accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation (DF) or fluctuation index ([Cmax - Ctau]/Css,avg]) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by anti-drug antibody (ADA) for BMS-986016 (all participants) and nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval from centrally read electrocardiograms (ECGs)</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) rates</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Neoplasms by Site</condition>
  <arm_group>
    <arm_group_label>Relatlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relatlimab (BMS-986016) specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatlimab + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986213</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relatlimab (BMS-986016) + Nivolumab (BMS-936558)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Relatlimab</intervention_name>
    <arm_group_label>Relatlimab</arm_group_label>
    <arm_group_label>Relatlimab + Nivolumab</arm_group_label>
    <other_name>BMS-986016</other_name>
    <other_name>Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Relatlimab + Nivolumab</arm_group_label>
    <other_name>Anti-PD-1 (Anti-Programmed-Death-1)</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986213</intervention_name>
    <description>Relatlimab + Nivolumab</description>
    <arm_group_label>BMS-986213</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer
             (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology
             agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to
             IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma
             subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or
             without anti-CTLA-4.

          -  For Dose Expansion: all of the above in escalation except for cervical, ovarian, and
             CRC

          -  Progressed, or been intolerant to, at least one standard treatment regimen, except for
             participants in 1st line cohorts.

          -  ECOG performance status between 0 and 2

          -  At least 1 lesion with measurable disease at baseline

          -  Availability of an existing tumor biopsy sample (and consent to allow pre-treatment
             tumor biopsy)

        Exclusion Criteria:

          -  Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the
             only site of active disease

          -  Autoimmune disease

          -  Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed
             consent

          -  Uncontrolled CNS metastases

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Nikanjam, Site 0043</last_name>
      <phone>858-822-0201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Lewis, Site 0053</last_name>
      <phone>720-848-7135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Khushalani, Site 0058</last_name>
      <phone>813-745-4398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gajewski, Site 0003</last_name>
      <phone>773-702-1679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrun Hallmeyer, Site 0048</last_name>
      <phone>847-410-0658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Lipson, Site 0004</last_name>
      <phone>410-502-5352</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Stephen Hodi, Site 0001</last_name>
      <phone>617-582-7603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Weise, Site 0011</last_name>
      <phone>313-576-8599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Block, Site 0051</last_name>
      <phone>507-284-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonel Hernandez Aya, Site 0044</last_name>
      <phone>314-747-7992</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Callahan, Site 0005</last_name>
      <phone>646-888-3359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Med Ctr</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Sanborn, Site 0002</last_name>
      <phone>503-215-5763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Nair, Site 0047</last_name>
      <phone>610-402-1184</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Eye and Ear Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Cowey, Site 0057</last_name>
      <phone>214-370-1840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Md Anderson Can Cnt</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hussein Tawbi, Site 0045</last_name>
      <phone>713-563-9451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Washington Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailender Bhatia, Site 0008</last_name>
      <phone>206-606-6765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgina Long, Site 0029</last_name>
      <phone>+61299117200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gallipoli Medical Research Foundation</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Atkinson, Site 0031</last_name>
      <phone>+61733947807</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tasman Oncology Research Pty Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hill, Site 0039</last_name>
      <phone>+61756132484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Au-Yeung, Site 0033</last_name>
      <phone>+61394969802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Millward, Site 0032</last_name>
      <phone>+61863825122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0049</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Claveau, Site 0050</last_name>
      <phone>4186912950</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0038</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0037</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0040</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0041</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Curigliano, Site 0014</last_name>
      <phone>+390257489599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Ascierto, Site 0013</last_name>
      <phone>+390815903431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto - I.R.C.C.S.</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanna Chiarion Sileni, Site 0035</last_name>
      <phone>+390498215938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4668560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>4118777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antoni Van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Wilgenhof, Site 0025</last_name>
      <phone>+31020646077</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Univ. Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Munoz, Site 0015</last_name>
      <phone>+34934893000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen De La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Trigo Perez, Site 0046</last_name>
      <phone>+34951032338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Melero, Site 0006</last_name>
      <phone>+34948286397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust - PPDS</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Lorigan, Site 0034</last_name>
      <phone>+441614446374</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms by Site</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

